S&S Healthcare Holding Ltd.

As of June 30, 2026, S&S Healthcare Holding Ltd. carries a market capitalization of 945.03M, placing it among publicly traded companies globally. Its enterprise value stands at 946.97M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, S&S Healthcare Holding Ltd. has 24.11M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 5.48, and the price-to-book ratio stands at 4.63.

These figures are as of June 30, 2026. The EV/Sales ratio of 5.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 946.97M versus a market cap of 945.03M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, S&S Healthcare Holding Ltd. maintains a current ratio of 2.85, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.71, indicating elevated leverage, while an interest coverage ratio of -33.04 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, S&S Healthcare Holding Ltd. posted a negative return on equity (ROE) of -18.18, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -11.19, reflecting losses generated across the asset base. The company generates approximately 2.08M in revenue per employee across its workforce of 83.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.28 indicates how many times S&S Healthcare Holding Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, S&S Healthcare Holding Ltd. recorded an income tax benefit of -578,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -42.79M and -40.47M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, S&S Healthcare Holding Ltd.'s stock has gained approximately 19.21% over the past 52 weeks. The 50-day moving average sits at 46.08, while the 200-day moving average is 39.75.

Over the twelve months ended June 30, 2026, S&S Healthcare Holding Ltd. generated 172.45M in revenue and converted that into -40.47M in net income, yielding earnings per share of -1.75. EBITDA reached -28.87M, while operating income came in at -50.32M.

As of June 30, 2026, S&S Healthcare Holding Ltd. holds 73.47M in cash and equivalents against 27.03M in total debt, resulting in a net debt position of -59.68M. Total book value stands at 204.00M, with working capital of 162.54M providing operational flexibility.

S&S Healthcare Holding Ltd. produced -34.83M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.04M in capital expenditures, free cash flow totaled -38.87M - equivalent to -1.61 per share.

Over the twelve months ended June 30, 2026, S&S Healthcare Holding Ltd. posted a gross margin of 33.62, reflecting its pricing power and cost economics. The operating margin of -29.18 and net profit margin of -23.47 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.12: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.50, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to S&S Healthcare Holding Ltd. shareholders.

S&S Healthcare Holding Ltd.'s most recent stock split took place on August 15, 2022 with a 5:1 split ratio.

As of June 30, 2026, S&S Healthcare Holding Ltd. has an Altman Z-Score of 5.80, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.